COVID-19: A Message from Our CEO


“As the COVID-19 pandemic evolves, Komipharm has committed to fast track clinical programs for treating COVID-19 patients with the US Food and Drug Administration (FDA), Italian Medicines Agency (AIFA) and the Korean Ministry of Food and Drug Safety (MFDS). Komipharm is confident for success, whereby treatment focus will extend to other countries in the European Union and Asia.

Komipharm remains committed to safeguarding our customers and our people. In keeping with our values-based culture, Komipharm has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to customers and public health” – Mr Yong-jin Yang, Chairman & CEO, Komipharm International Australia Pty Ltd